title: [Treatment of transformed refractory migraine with intravenous dihydroergotamine].
abstract: In this work we present our experience with a seven-day protocol of i.v. dihydroergotamine (DHE) in the treatment of 6 patients (7 treatments) suffering from intractable transformed migraine. All of them were admitted to hospital and treated for one week with a protocol which included DHE doses between 0.5-1 mg/8 h. One patient did not respond. The remaining 6 became free of pain in under 48 hours after the beginning of treatment. This positive effect remained for between 15 days and 3 months. All patients experienced adverse events; however, these were slight and ceased when the DHE dose was reduced. DHE is an effective and quick option for the short-term treatment of patients with severe transformed migraine resistant to other medications.
authors.affiliation: Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander.
authors.forename: C
authors.initials: C
authors.lastname: Cid
authors.forename: F
authors.initials: F
authors.lastname: Ortega-Valín
authors.forename: M
authors.initials: M
authors.lastname: Valero
authors.forename: R
authors.initials: R
authors.lastname: Muñoz
authors.forename: J
authors.initials: J
authors.lastname: Pascual
mesh_terms: D000328:Adult; D004087:Dihydroergotamine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D004087:Dihydroergotamine
vernacular_title: Tratamiento de la migraña transformada refractaria con dihidroergotamina intravenosa.